Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Q2 FY27 Earnings Presentation
20 slides from Alivus Life Sciences's earnings presentation, Oct 29, 2026
Slide 1: Exchange filing cover letter
October 29, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322
Slide 2: Investor Presentation Q2 FY27
Investor Presentation Q2 FY27
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Financial Performance Review
Financial Performance Review 3
Slide 5: Q2 FY27 Highlights
Q2 FY27 | Highlights “Q2FY27 was another strong quarter for us, with revenue growing 16.0% YoY, supported by healthy demand across all key markets and robust contributions from recent launches. Non- GPL business momentum was maintained, while CDMO business saw a meaningful pick-up Dr. Yasir Rawjee d
Slide 6: Q2 & H1 FY27 Performance
Q2 & H1 FY27 Performance Revenue EBITDA PAT EPS (In ₹ Mill i on ) (In ₹ Mill i on ) 41.8% (In ₹ Mill i on ) 28.9% (In ₹) 36.4% 36.6% 25.0% 1,968 6,891 34.4% 23.6% 6,820 22.1% 22.3% 16.02 33.0% 6,729 2,851 6,404 1,627 13.23 1,601 13.04 2,452 2,373 1,503 2,341 12.25 5,880 1,301 10.60 1,939 Q2FY26 Q3FY
Slide 7: P&L Highlights | Q2 & H1 FY27
P&L Highlights | Q2 & H1 FY27 Particulars (In ₹ Million) Q2FY27 Q1FY27 QoQ Q2FY26 YoY H1FY27 H1FY26 YoY FY26 Revenue from Operations 6,820 6,404 6.5% 5,880 16.0% 13,224 11,898 11.1% 25,518 Gross Profit 4,391 3,854 13.9% 3,391 29.5% 8,245 6,706 22.9% 14,853 Gross Profit (%) 64.4% 60.2% +420 bps 57.7%
Slide 8: Healthy Return Indicators
Healthy Return Indicators ROICE (%) Fixed Assets Turnover (Times) 34% 34% 32% 2.9 30% 2.7 27% 2.5 2.2 2.1 FY23 FY24 FY25 FY26 H1FY27 FY23 FY24 FY25 FY26 H1FY27 • ROICE expanded to ~34% – underscoring strong asset productivity and disciplined capital allocation. • FATR is 2.1 times – Asset turns rema
Slide 9: Business Performance Review
Business Performance Review 8
Slide 10: Segmental Performance | Generic API vs CDMO
Segmental Performance | Generic API vs CDMO Generic API CDMO (Revenu e In ₹ Milli o n ) (Revenu e In ₹ Milli o n ) 556 6,343 500 6,070 6,063 453 5,921 5,464 378 278 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 • Generic API revenues in Q2FY27 saw a strong • CDMO business saw
Slide 11: Segmental Performance | GPL vs Non-GPL
Segmental Performance | GPL vs Non-GPL GPL % of Total Revenue Non-GPL % of Total Revenue (In ₹ Mill i on ) (In ₹ Mill i on ) 35.4% 88.7% 30.0% 75.6% 78.7% 5,681 2,439 70.0% 64.6% 24.4% 21.3% 5,369 2,018 4,711 4,443 4,452 1,437 11.3% 1,451 723 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q
Slide 12: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Mix 19% 17% 15% 17% 15% 31% 26% 34% 35% 33% Emerging Markets Acute 81% 83% 85% 83% 85% Regulated 69% 74% 66% 65% 67% Chronic Markets Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 • Regulated markets contributed 85% of Q2F
Slide 13: Company Overview
LIFE SCIENCES Company Overview ¢
Slide 14: Global Footprint
Global Footprint • Filed 630 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 370+ 30+ 164 188 70+ 10+ 123 23 170+ 630 50+ 10+ DMFs and 105 27 (Brazil) CEPs 13 Regulated Emerging India - Mix of Regulated Number of
Slide 15: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend (In ₹ Mill i on ) Therapy North America Europe Japan Brazil Australia ROW Total % of Total Revenue CVS 40 42 4 28 12 41 167 CNS 45 28 8 23 4 23 131 Anti-Infective 21 11 3 3 3 15 56 3.9% Diabetes 10 5 - 9 2 19 45 3.6% Dermatology 10 6 1 14 1 11 43 3
Slide 16: Quality Focused Manufacturing and R&D Infrastructure
Quality Focused Manufacturing and R&D Infrastructure Manufacturing Infrastructure R&D Infrastructure* Annual Installed Last USFDA Location Approvals Mahape, Navi Mumbai Capacity Inspection Date USFDA, MHRA (UK), FIMEA ▪ R&D for new product (Finland), Romania (Europe) PMDA development and complex Ank
Slide 17: Strategy Going Forward
LIFE SCIENCES Strategy Going Forward 6
Slide 18: Strategy Growth Levers
Strategy Growth Levers 1 Gx API Business ✓ New product launches New Growth levers 2 ✓ Geographical expansion ✓ Focus on new markets becoming more regulated ✓ CDMO Ramp up ✓ Pursue 2nd source opportunities with top generic players ✓ Expand into complex API platforms ✓ Iron compounds ✓ Oncology & HP A
Slide 19: Future Capacity Expansion
Future Capacity Expansion Operational Expansion Type Division Location Status & Planned Capacity Timelines Brownfield API / Intermediate Ankleshwar Planned addition of ~100KL Capacity Q4 FY27 Brownfield API Dahej Planned addition of ~160KL Capacity Q3 FY27 Phase 1 - ~340 KL (Intermediate block and B
Slide 20: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: [email protected] ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE SNEHA SALIAN Email: [email protected] Email: [email protected] CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979 Technopolis Knowledge Park, A Wing, P